Moderna Cuts R&D by $1.1B, Focus on Key Approvals
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
- Latest
- Trending
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
New holistic cybersecurity offering enhances data protection for East African businesses with innovative solutions.
Navient to pay $120M and face US student loan ban to resolve CFPB lawsuit over lending failures and borrower mistreatment.
Ant Group refinances to boost overseas ventures, allocating $1.5B for Ant International.
Iranian cyber group OilRig targets Iraqi government using malware Veaty and Spearal for sophisticated cyber espionage.
Discover why Amazon is Berkshire Hathaway's leading AI stock with unmatched innovation and growth potential.
Codelco reaches early contract agreements at El Teniente and Ministro Hales, ensuring stability and potential productivity boost.
OpenAI seeks $6.5 billion, boosting its valuation to $150 billion, making it one of the most valuable private companies worldwide.
Deutsche Bank gives Buy ratings to Star Bulk and Genco, citing strong fundamentals and attractive valuations in maritime shipping.
PayPal and Venmo integrate Ethereum Name Service to simplify crypto transfers, enhancing user experience and promoting crypto adoption.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.